Last reviewed · How we verify
Mirabegron with vaginal estrogen cream
Mirabegron relaxes bladder smooth muscle via beta-3 adrenergic receptor agonism, while vaginal estrogen cream restores local vaginal tissue health and reduces urogenital atrophy symptoms.
Mirabegron relaxes bladder smooth muscle via beta-3 adrenergic receptor agonism, while vaginal estrogen cream restores local vaginal tissue health and reduces urogenital atrophy symptoms. Used for Overactive bladder with urge incontinence, Genitourinary syndrome of menopause with urogenital atrophy.
At a glance
| Generic name | Mirabegron with vaginal estrogen cream |
|---|---|
| Also known as | Betmiga and Premarin |
| Sponsor | Mackay Memorial Hospital |
| Drug class | Beta-3 adrenergic agonist (mirabegron) + topical estrogen (vaginal cream) |
| Target | Beta-3 adrenergic receptor (mirabegron); estrogen receptor alpha and beta (vaginal estrogen) |
| Modality | Small molecule |
| Therapeutic area | Urology / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Mirabegron is a beta-3 adrenergic agonist that increases bladder capacity and reduces detrusor contractions, improving overactive bladder symptoms. Vaginal estrogen cream provides localized estrogen replacement to restore vaginal epithelial thickness, elasticity, and moisture, addressing genitourinary syndrome of menopause and urogenital atrophy. The combination addresses both the neurogenic bladder dysfunction and the underlying tissue atrophy contributing to lower urinary tract symptoms.
Approved indications
- Overactive bladder with urge incontinence
- Genitourinary syndrome of menopause with urogenital atrophy
Common side effects
- Hypertension
- Headache
- Tachycardia
- Vaginal irritation or discharge
- Nasopharyngitis
Key clinical trials
- Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (PHASE4)
- Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (PHASE4)
- Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: